2008

Morris, J. K. & Savva, G. M. The risk of fetal loss following a prenatal diagnosis of trisomy 13 or trisomy 18, Am.J.Med.Genet.A, vol. 146, no. 7, pp. 827-832.

Morris, J. K., Bestwick, J., & Wald, N. J. Multiple marker screening for Down's syndrome: a method of assessing the statistical robustness of proposed tests., J.Med.Screen., vol. 15, pp. 55-61.

Wald, N. J., Huttly, W. J., & Bestwick, J. P. Inhibin-A concentrations between 14 and 22 weeks of gestation, Prenat.Diagn., vol. 28, no. 4, pp. 360-361.

Wald, N. J., Bestwick, J. P., & Canick, J. A. Contingent screening for Down Syndrome (Response to Cuckle et al.), Prenat.Diagn., vol. 28, no. 8, p. 781

 

2007

Barnes, I. M., Bestwick, J. P., & Larsen, S. O. Setting truncation limits for marker values in medical screening, J.Med.Screen., vol. 14, no. 2, pp. 103-106.

Crane, E. & Morris, J. K. Paternal age and birth defects: how strong is the association, Hum.Reprod., vol. 22, no. 8, pp. 2349-2350.

Morris, J. K. & Wald, N. J. The effect of correlations between screening markers on screening performance, J.Med Screen., vol. 14, no. 3, pp. 151-157.

Morris, J. K. & Wald, N. J. Prevalence of neural tube defect pregnancies in England and Wales from 1964 to 2004, J.Med Screen., vol. 14, no. 2, pp. 55-59.

Morris, J. K. & Wald, N. J. Estimating the risk of Down's syndrome in antenatal screening and the gestation at which this risk applies, J.Med Screen., vol. 14, no. 1, pp. 5-7.

Wald, N. J. & Oakley, G. P. Should folic acid fortification be mandatory? Yes, BMJ, vol. 334, no. 7606, p. 1252.

Wald, N. J., Bestwick, J. P., Barnes, I. M., & Kellner, L. H. Anomalous marker patterns in Down syndrome screening, Prenat.Diagn., vol. 27, no. 2, pp. 185-186.

Wald, N. J., Bestwick, J. P., & Morris, J. K. Truncation limits for CT marker ratios in prenatal screening for Down syndrome, Prenat.Diagn., vol. 27, no. 2, pp. 187-188

Weisz, B., Pandya, P. P., David, A. L., Huttly, W., Jones, P., & Rodeck, C. H. Ultrasound findings after screening for Down syndrome using the integrated test, Obstet.Gynecol., vol. 109, no. 5, pp. 1046-1052.

Weisz, B., Pandya, P., Chitty, L., Jones, P., Huttly, W., & Rodeck, C. Practical issues drawn from the implementation of the integrated test for Down syndrome screening into routine clinical practice, BJOG., vol. 114, no. 4, pp. 493-497.

 

2006

Crane E, Morris JK. Changes in maternal age in England and Wales - implications for Down syndrome. Downs Syndr Res Pract July 2006; 10: 41-43. ISSN: 09687912.

Huttly WJ, Morris JK, Bestwick JP, Wald NJ, Murphy K, Pandya PP. Three stage contingent screening for Down syndrome Prenat Diagn 2006; 26: 1183. ISSN: 01973851.

Savva GM, Morris JK, Mutton DE, Alberman E. Maternal age-specific fetal loss rates in Down syndrome pregnancies. Prenat Diagn June 2006; 26: 499-504. ISSN: 01973851.

Wald NJ, Barnes IM, Birger R, Huttly W. Effect on Down syndrome screening performance of adjusting for marker levels in previous pregnancy. Prenat Diagn 2006; 26: 539-544. ISSN: 01973851.

Wald NJ, Barnes IM, Birger R, Huttly W. Erratum: Effect on Down syndrome screening performance of adjusting for marker levels in a previous pregnancy. Prenat Diagn 2006; 26: 589. ISSN: 01973851.

Wald NJ, Bestwick JP, Morris JK. Cross-trimester marker ratios in prenatal screening Down syndrome. Prenat Diagn2006; 26: 514-523. ISSN: 01973851.

Wald NJ, Bestwick JP, Huttly WJ, Morris JK, George LM. Validation plots in antenatal screening for Down’s syndrome. J Med Screen 2006; 13: 166-177. ISSN: 09691413.

Wald NJ, Morris JK, Ibison J, Wu T, George LM. Screening in early pregnancy for pre-eclampsia using Down syndrome quadruple test markers. Prenat Diagn 2006; 26: 559-564. ISSN: 01973851.

Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM, Bestwick JP. Erratum: Correction to SURUSS Report. J Med Screen 2006; 13: 51-52. ISSN: 09691413.

Wald NJ, Rudnicka AR. Antenatal screening for Down syndrome using the Integrated test. In, Van Vugt JMG, Shulman LP (Eds) Prenatal Medicine. Taylor & Francis, New York, 2006, 79-102. ISBN: 0824728440.

Wald NJ, Rudnicka AR, Bestwick JP. Sequential and contingent prenatal screening for Down syndrome. Prenat Diagn2006; 26: 769-777. ISSN: 01973851.

 

2005

Kovaleva NV, Mutton DE. Epidemiology of double aneuploidies involving chromosome 21 and the sex chromosomes. Am J Med Genet 2005; 134A: 24-32. ISSN: 01487299.

Morris JK, De Vigan C, Mutton DE, Alberman E. Risk of a Down syndrome live birth in women 45 years of age and older. Prenat Diagn 2005; 25: 275-178. ISSN: 01973851.

Wald NJ . Which gestational age estimate to use in AFP screening for spina bifida? Prenat Diagn 2005;25:623.

Wald, NJ, Morris, JK, Rish, S. The efficacy of combining several risk factors as a screening test. J Med Screen 2005; 12: 197-201. ISSN: 09691413.

Wald NJ, Rodeck C, Hackshaw AK, Rudnicka A. SURUSS in perspective. (Reprinted) Semin Perinatol 2005; 29:225-235. ISSN: 01460005.

Wald NJ, Rodeck C, Hackshaw AK, Rudnicka A. Author’s reply (Response to Alfirevic). Br J Obstet Gynecol 2005; 112: 128. ISSN: 03065456.

 

2004

Huttly W, Rudnicka A, Wald NJ. Second trimester prenatal screening markers for Down syndrome in women with Insulin-Dependent Diabetes Mellitus. Prenat Diagn 2004; 24: 804-807. ISSN: 01973851.

Kovaleva NV, Mutton DE. Epidemiology of double aneuploidies involving chromosome 21 and the sex chromosomes. Am J Med Genet 2004; 9999:1-9. ISSN: 01487299.

Wald NJ. First trimester screening for Down’s Syndrome. N Engl J Med 2004; 350: 619-620. ISSN: 00284793.

Wald NJ. Folic acid and prevention of neural tube defects. New Engl J Med 2004; 350: 2210-2211. ISSN: 00284793.

Wald NJ. In response to Nicolaides. Prenat Diagn 2004; 24:317-318. ISSN: 01973851.

Wald NJ, Huttly WJ, Rudnicka AR. Prenatal screening for Down syndrome: The problem of recurrent false-positives. Prenat Diagn 2004; 24:389-392. ISSN: 01973851.

Wald NJ, Huttly WJ, Rudnicka AR. Recurrent false-positives in AFP screening for open Neural tube defects. Prenat Diagn 2004; 24: 1018-1019. ISSN: 01973851.

Wald NJ, Law M, Hoffbrand VA. Folic acid fortification in the prevention of neural tube defects. Am J Clin Nutr 2004; 80:1665. ISSN: 00029165.

Wald NJ, Rodeck CR, Hackshaw AK, Rudnicka A. Correlations between nuchal transculency and serum markers in SURUSS. Prenat Diagn 2004; 24:835-836. ISSN: 01973851.

Wald NJ, Rodeck CR, Hackshaw AK, Rudnicka A. SURUSS in perspective. Br J Obstet Gynaecol 2004;111:521-531. ISSN: 00297844

Wald NJ, Rodeck CR, Rudnicka A, Hackshaw AK. In response to Nicolaides. Prenat Diagn 2004; 24:319-320. ISSN: 01973851.

Wald NJ, Rodeck C, Rudnicka AR, Hackshaw AK. Nuchal translucency and gestational age. Prenat Diagn 2004; 24:150-153. ISSN: 01973851.

Wald NJ, Rodeck CR, Rudnicka A, Hackshaw AK. Response to Nicolaides. Prenat Diagn 2004; 24:834-834. ISSN: 01973851.

 

2003

Alberman E, Huttly W, Hennessy E, McIntosh A. The use of record linkage for auditing the uptake and outcome of prenatal serum screening and prenatal diagnostic tests for Down syndrome. Prenat Diagnosis 2003;23:801-806. pISSN: 01973851.

Huang T, Alberman A, Watt HC, Wald NJ. Using Down syndrome serum screening results to predict low birthweight. Prenat Diagn 2003;23:420-426. pISSN: 01973851.

Morris JK, Wald NJ, Mutton DE, Alberman E. Comparison of models of maternal age-specific risk for Down syndrome live births. Prenat Diagn 2003;23:252-258. pISSN: 01973851.

Oakley G, Wald N, Ommen G. Provide the citizens of New Zealand the miracle of folic acid fortification. N Z Med J 2003;116:U302. pISSN: 00288446.

Smith-Bindman R, Chu P, Bacchetti P, Waters JJ, Mutton D, Alberman E. Prenatal screening for Down syndrome in England and Wales and population-based birth outcomes. Am J Obstet Gynecol 2003;189:980-985. pISSN: 00029378.

Wald N. Certification of competence in performing specific procedures of tests in screening practice. Prenat Diagn 2003;23:861. pISSN: 01973851.

Wald NJ, Huttly WJ, Hackshaw AK. Antenatal screening for Down's syndrome with the quadruple test. Lancet 2003;361:835-836. pISSN: 01406736.

Wald NJ, Rish S, Hackshaw AK. Combining nuchal translucency and serum markers in prenatal screening for Down syndrome in twin pregnancies. Prenat Diagn 2003;23:588-592. p ISSN: 01973851.

Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess 2003;7:i-iv,1-88. pISSN: 13665278.

Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 2003;10:56-104. pISSN: 09691413.

 

2002

Alberman E. The National Down Syndrome Cytogenetic Register (NDSCR). J Med Screen 2002;9:97-98. ISSN: 09691413.

Hackshaw A, Wald NJ. Reporting partial screening results: is it confusing and unsatisfactory (reply to Mulvey and Wallace). Prenat Diagn 2002;22: 633-634. ISSN: 01973851.

Hackshaw A, Wald N. Estimation of risk in second trimester serum screening for Down syndrome among women who have already had first trimester screening. Prenat Diagn 2002;22: 1051-1053. ISSN: 01973851.

Morris JK, Mutton DE, Alberman E. Potential biases in Down syndrome birth prevalence estimation. J Med Screen 2002;9:192. ISSN: 09691413

Morris JK, Mutton DE, Alberman E. Revised estimates of the maternal age specific live birth prevalence of Down's syndrome. J Med Screen 2002;9:2-6. ISSN: 09691413

Rudnicka AR, Wald NJ, Huttley W, Hackshaw AK. Influence of maternal smoking on the birth prevalence of Down syndrome and on second trimester screening performance. Prenat Diagn 2002;22:893-897. ISSN: 01973851

Wald D, Law M, Wald N. The serum folate response to the US mandatory fortification of grain products with folic acid. Arch Int Med 2002;162:2254. ISSN: 00039926

Wald N. Should we adopt folic acid fortification in Europe? Reprod Toxicol 2002;16:A403. ISSN: 08906238

Wald N. First-trimester nuchal translucency screening. J Ultrasound Med 2002;21:481, discussion 483-487. ISSN: 02784297

Wald NJ, Canick JA. Seeking other disorders within antenatal serum screening programmes for Down's syndrome. J Med Screen 2002;9:145-146. ISSN: 09691413

Wald NJ, Hackshaw AK. Folic acid supplementation and neural tube defects. Am J Med Genet 2002;109:79. ISSN: 01487299

Wald NJ, Huttley W, Hackshaw AK. Audit of Down's syndrome screening is not valid. BMJ 2002;325:1034. ISSN: 09598138

 

2001

Hackshaw AK, Wald NJ. Assessment of the value of reporting partial screening results in prenatal screening for Down syndrome. Prenat Diagn 2001;21:737-740. ISSN: 01973851

Hackshaw AK, Wald NJ. Repeat testing in antenatal screening for Down's syndrome using dimeric inhibin-A in combination with other maternal serum markers. Prenat Diagn 2001;21:58-61. ISSN: 01973851

Hackshaw AK, Wald NJ. Inaccurate estimation of risk in second trimester serum screening for Down syndrome among women who have already had first trimester screening. Prenat Diagn 2001;21: 741-746. ISSN: 01973851

Hackshaw AK, Wald NJ, George LM. Measuring serum markers once or twice in each assay in antenatal screening for Down syndrome and neural tube defects. Prenat Diagn 2001;21:72-73. ISSN: 01973851

Hackshaw AK, Wald NJ, George LM. Reply to Peter Benn. Prenat Diagn 2001;21:894-899. ISSN: 01973851

Hermon C, Alberman E, Beral V, Swerdlow AJ for The Collaborative Study Group of Genetic Disorders. Mortality and cancer incidence in persons with Down's syndrome, their parents and siblings. Ann Hum Genet 2001;65:167-176. ISSN: 00034800

Sasieni P, Cuzick J, Boyle P, Craddock P, Hince T, Kitchener H, Lilleyman J, McEwen J, Miles R, Roche M, Slevin M, Vessey M, Wald N, Wilkins N, Young N. Routine audit is an ethical requirement of screening, BMJ 2001;322:1179. ISSN: 09598138

Wald NJ. Guidance on terminology. J Med Screen 2001;8:56. ISSN: 09691413

Wald NJ. All screening is universal. J Med Screen 2001;8:169. ISSN: 09691413

Wald NJ. Folic acid and neural tube defects. Bibl Nutr Dieta 2001;55:22-23. ISSN: 00678198

Wald NJ. The definition of screening. J Med Screen 2001;8:1. ISSN: 09691413

Wald NJ, Hackshaw AK. Folic acid and miscarriage: An unjustified link Am J Med Genet 2001;98:204. ISSN: 01487299

Wald NJ, Law MR, Morris JK, Wald DS. Quantifying the effect of folic acid. Lancet 2001;358:2069-2073. ISSN: 01406736

 

2000

Cuckle HS, Wald N. Tests using single markers. In Antenatal and Neonatal Screening, 2nd ed. Wald NJ, Leck I. (Eds). Oxford, Oxford University Press, 2000, 3-22. ISBN: 0192628267

Gosden C, Tabor A, Leck I, Grant A, Alfirevic Z, Wald N. Amniocentesis and chorionic vullus sampling. In Antenatal and Neonatal Screening, 2nd ed. Wald NJ, Leck I. (Eds). Oxford, Oxford University Press, 2000, 470-516. ISBN: 0192628267

Hackshaw AK, Wald NJ. Revised distribution parameters for serum markers for trisomy 18. J Med Screen 2000;7:215. ISSN: 09691413

Morris J, Wald N. Down syndrome fetal loss rate in early pregnancy (response to Cuckle). Prenat Diagn 2000;20:683-686. ISSN: 01973851

Wald N. Down's syndrome. In Antenatal and Neonatal Screening, 2nd ed. Wald NJ, Leck I. (Eds). Oxford, Oxford University Press, 2000, 85-115. ISBN: 0192628267

Wald N. Neural tube defects. In Antenatal and Neonatal Screening, 2nd ed. Wald NJ, Leck I. (Eds). Oxford, Oxford University Press, 2000, 61-84. ISBN: 0192628267

Wald NJ, Dormandy ER. Reporting of screening results (authors' reply). J Med Screen 2000;7:54. ISSN: 09691413

Wald NJ, Hackshaw AK. Advances in antenatal screening for Down syndrome. Baillieres Best Pract Res Clin Obstet Gynaecol 2000;14:563-580. ISSN: 09503552

Wald N, Hackshaw A. Tests using multiple markers. In Antenatal and Neonatal Screening, 2nd ed. Wald NJ, Leck I. (Eds). Oxford, Oxford University Press, 2000, 23-57. ISBN: 0192628267

Wald NJ, Hackshaw AK, Cuckle HS. Maternal serum alphafetoprotein screening for open neural tube defects. revised statistical parameters. Br J Obstet Gynaecol 2000;107:296-298. ISSN: 03065456

Wald NJ, Hackshaw AK, George L. Assay precision of serum alpha-fetoprotein in antenatal screening for neural tube defects and Down's syndrome. J Med Screen 2000;7:74-77. ISSN: 09691413

Wald NJ, Hackshaw AK, Huttly W. Serum screening programmes are effective and safe. BMJ 2000;321:763-764. ISSN: 09598138

Wald NJ, Hackshaw AK, Watt H. Nuchal translucency and trisomy 18. Prenat Diagn 2000;20:353-354. ISSN: 01973851

Wald NJ, Kennard A, Donnenfeld A, Leck I. Ultrasound scanning for congenital abnormalities. In Antenatal and Neonatal Screening, 2nd ed. Wald NJ, Leck I. (Eds). Oxford, Oxford University Press, 2000, 441-469. ISBN: 0192628267

Wald NJ, Leck I. editors: Antenatal and Neonatal Screening, 2nd ed , Oxford, Oxford University Press, 2000. ISBN: 0192628267. Please click here for the publisher's web site

Wald NJ, Leck I. Conclusions. In Antenatal and Neonatal Screening, 2nd ed. Wald NJ, Leck I. (Eds). Oxford, Oxford University Press, 2000, 556-567. ISBN: 0192628267

Wald NJ, Leck I, Muir Gray JA. Ethics of antenatal and neonatal screening. In Antenatal and Neonatal Screening, 2nd ed. Wald NJ, Leck I. (Eds). Oxford, Oxford University Press, 2000, 543-555. ISBN: 0192628267

 

1999

Alberman E, Noble JM. Commentary: Food should be fortified with folic acid. BMJ 1999;319:93

Dormandy E. Antenatal screening. Better understanding of factors influencing uptake is needed. BMJ 1999;318:805

Hackshaw A, Wald N, Ayme S. Statement from Panel on Antenatal Screening for Down syndrome. In: Down Syndrome Screening Policy and Economic Evaluations. Beazoglou T, Benn P, Cuckle H, Haddow J, Kyriopoulos J (eds). Exandus, Athens, 1999, 261-265. ISBN: 960-256-370-2

Hook EB, Cross PK, Mutton DE. Female predominance (low sex ratio) in 47,+21 mosaics. Am J Med Genet 1999;84:316-319. ISSN: 01487299

Huttly WJ, Wald NH, Walters JC. Folic acid supplementation before pregnancy remains inadequate. BMJ 1999;319:1499

Morris JK, Wald NJ. Quantifying the decline in the birth prevalence of neural tube defects in England and Wales. J Med Screen 1999;6:182-185

Morris JK, Wald NJ, Watt, HC. Fetal loss in Down syndrome pregnancies. Prenat Diagn 1999;19:142-145

Wald NJ, Dormandy EF. Reporting of screening results. J Med Screen 1999;6:117-118

Wald NJ, Hackshaw AK. Development and implementation of Down's syndrome screening. In: Down Syndrome Screening Policy and Economic Evaluations. Beazoglou T, Benn P, Cuckle H, Haddow J, Kyriopoulos J (eds). Exandus, Athens, 1999, 43-54. ISBN: 960-256-370-2

Wald NJ, Hackshaw AK, Diamandis EP, Melegos DN. Maternal serum prostate-specific antigen and Down syndrome in the first and second trimesters of pregnancy. Prenat Diagn 1999;19:674-676

Wald NJ, Hackshaw AK, Frost CD. When can a risk factor be used as a worthwhile screening test? BMJ 1999;319:1562-1565

Wald NJ, Hackshaw, Watt H. Nuchal translucency and trisomy 18. Prenat Diagn 1999;19:995-996

Wald NJ, Huttly WJ. Validation of risk estimation using the quadruple test in prenatal screening. Prenat Diagn 1999;19:1083-1084

Wald NJ, Huttly WJ, Hennessy CF. Down's syndrome screening in the UK in 1998. Lancet 1999;354:1264

Wald NJ, Noble J. Primary prevention of neural tube defects. In: Fetal Medicine: Basic Science and Clinical Practice. Rodeck CH, Whittle MJ (eds). London, Churchill Livingstone, 1999, 283-290. ISBN: 0-4430-5357X

Wald NJ, Watt HC. The target plot: a new way of displaying the performance of a screening test. J Med Screen 1999;6:195-199

Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters. N Engl J Med 1999;341:461-467

Wald NJ, Watt HC, Norgaard-Pedersen B, Christiansen M. SP1 in pregnancies with Down syndrome in the first trimester of pregnancy. Prenat Diagn 1999;19:517-520

Wald NJ, White N, Morris JK, Huttly WJ, Canick JA. Serum markers for Down's syndrome in women who have had in vitro fertilisation: implications for antenatal screening. Br J Obstet Gynaecol 1999;106:1304-1306

Watt HC, Wald NJ, Huttly WJ. Inhibin-A regression. Prenat Diagn 1999;19:893-894

 

1998

Hackshaw A, Densem J, Wald N. (1998). Repeat maternal serum testing for Down's syndrome screening using multiple markers with special reference to free a ; and free b (Correction). Prenat Diagn 18: 525-526

Huang T, Watt H, Wald N, Morris J, Mutton D, Alberman E, Kelekun C. (1998). Birth prevalence of Down's syndrome in England and Wales 1990 to 1997. J Med Screen 5: 213-214

Morris JK, Alberman ED, Mutton DE. (1998). Is there evidence of clustering in Down syndrome? Int J Epidemiol 27: 495-498

Mutton DE, Ide RG, Alberman ED. (1998). Changing trends in prenatal screening and diagnosis for Down syndrome: England and Wales 1989-1997. BMJ 317: 922-923

Noble J. (1998). Natural history of Down's syndrome: a brief review for those involved in antenatal screening. J Med Screen 5: 172-177

Schuchter K, Wald NJ, Hackshaw AK, Hafner E, Liebhardt E. (1998). The distribution of nuchal translucency at 10-13 weeks of pregnancy. Prenat Diagn 18: 281-286

Wald N. (1998). First-trimester screening for Down syndrome: the 'combined' test. Israel J Obstet Gynecol 9: 59-60

Wald NJ, Hackshaw AK. (1998). Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome (Authors' reply to Reynolds et al. ). Prenat Diagn 18: 515-518

Wald NJ, Hackshaw AK. (1998). Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome (Authors' reply to Nicolaides et al. ). Prenat Diagn 18: 521-523

Wald NJ, Kennard A. (1998). Routine ultrasound scanning for congenital abnormalitites. Ann NY Acad Sci 847: 173-180

Wald NJ, Law M, Jordan R. (1998). Folic acid food fortification to prevent neural tube defects. Lancet 351: 834

Wald NJ, Watt HC, Haddow JE, Knight GJ. (1998). Screening for Down's syndrome at 14 weeks of pregnancy. Prenat Diagn 18: 291-293

Watt HC, Wald NJ. (1998). Alternative methods of maternal weight adjustment in maternal serum screening for Down's syndrome and neural tube defects. Prenat Diagn 18: 842-845

Watt HC, Wald NJ, Huttly WJ. (1998). The pattern of maternal serum Inhibin-a concentrations in the second trimester of pregnancy. Prenat Diagn 18: 846-848

 

1997

Bower C, Wald NJ. (1997). Neural tube defects. In: Fetal Therapy. Invasive and Transplacental. Fisk NM, Moise KN (Eds). Cambridge: Cambridge University Press 39-49

Hackshaw AK. (1997). Developments in antenatal screening for Down's syndrome. Reverberations (UK Association of Sonographers) 15-18

Huang T, Watt HC, Wald NJ. (1997). The effect of differences in the distribution of maternal age in England and Wales on the performance of prenatal screening for Down's syndrome. Prenat Diagn 17: 615-621

Huang T, Watt HC, Wald NJ, Morris JK, Mutton D, Alberman E. (1997). Reliability of statistics on Down's syndrome notifications. J Med Screen 4: 95-97

Wald NJ. (1997). Systematic reviews of screening. J Med Screen 4: 59

Wald NJ, Hackshaw AK. (1997). Combining ultrasound and biochemistry in first-trimester screening for Down's sydnrome. Prenat Diagn 17: 821-829

Wald NJ, Hackshaw AK. (1997). Folic acid and prevention of neural-tube defects. Lancet 350: 664-665

Wald NJ, Hackshaw AK. (1997). Screening using risk estimation: uses and abuses of the method. In: Screening for Down Syndrome in the First Trimester. Grudzinskas JG, Ward RHT (Eds). London: RCOG Press, 45-53

Wald NJ, Kennard A, Hackshaw A, McGuire A. (1997). Antenatal screening for Down's syndrome. J Med Screen 4: 181-246

Wald NJ, Rodeck CH. (1997). Fetal nuchal translucency test for Down's syndrome: The principal investigators respond. Lancet 350: 1632

Williamson P, Alberman E, Rodeck C, Fiddler M, Church S, Harris R (on behalf of the Steering Committee of the National Confidential Enquiry into Counselling for Genetic Disorders). (1997). Antecedent circumstances surrounding neural tube defect births in 1990-1991. Br J Obstet Gynaecol 104: 51-56

 

1996

Brookes ME, Alberman E. (1996). Early mortality and morbidity in children with Down's syndrome diagnosed in two regional health authorities in 1989. J Med Screen 3: 7-11

Hacksaw AK, Wald NJ, Haddow JE. (1996). Down's syndrome screening with nuchal translucency. Lancet 348: 1740

Mutton D, Alberman E, Hook EB for The National Down Syndrome Cytogenetic Register and the Association of Clinical Cytogeneticists. (1996). Cytogenetic and epidemiological findings in Down syndrome, England and Wales 1989 to 1993. J Med Genet 33: 387-394

Noble J. (1996). Folic acid: preventing neural tube defects. Practice Nursing 7: 31-34

Noble J. (1996). The natural history of Down syndrome. Genetics and Teratology 5(2)

Noble J, Wald N. (1996). Preventing neural tube defects through folic acid supplementation. Health Visitor 69: 74-75

Wald N. (1996). Biochemical antenatal screening for open neural tube defects. Association of Clinical Pathologists Year Book 1996 13-14

Wald NJ. (1996). The B4-you-conceive pill. Lancet 348: 1460

Wald NJ, Densem JW, George L, Muttukrishna S, Knight PG. (1996). Prenatal screening for Down's syndrome using inhibin-A as a serum marker. Prenat Diagn 16: 143-153. (Correction: Prenat Diagn 17:285-290)

Wald NJ, George L. (1996). Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. Br J Obstet Gynaecol 103: 1173-1174

Wald NJ, George L, Hackshaw A. (1996). Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. Br J Obstet Gynaecol 103: 1174-1175

Wald NJ, George L, Smith D, Densem JW, Petterson K on behalf of the International Prenatal Screening Research Group. (1996). Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. Br J Obstet Gynaecol 103: 407-412

Wald NJ, Hacksaw AK. (1996). Risk estimation in Down's syndrome screening. Prenat Diagn 16: 1055-1060

Wald NJ, Hackshaw AK, Stone R, Sourial NA. (1996). Blood folic acid and vitamin B12 in relation to neural tube defects. Br J Obstet Gynaecol 103: 319-329

Wald NJ, Huttly W, Wald K, Kennard A. (1996). Down's syndrome screening in UK. Lancet 347: 330

Wald NJ, Kennard A. (1996). Prenatal screening for neural tube defects and Down's syndrome. In: Emery and Rimoin's Principles and Practice of Medical Genetics (Third Edition). Rimoin DL, Connon JM, Pyeritz RE (Eds). Edinburgh: Churchill Livingstone; 545-562

Wald NJ, Watt HC. (1996). Serum markers for Down's syndrome in relation to number of previous births and maternal age. Prenat Diagn 16: 699-703

Watt HC, Wald NJ, George L. (1996). Maternal serum inhibin-A in pregnancies with insulin dependent diabetes mellitus: Implications for screening for Down's syndrome. Prenat Diagn 16: 923-926

Watt HC, Wald NJ, George L. (1996). Maternal serum inhibin-A levels in twin pregnancies: Implications for screening for Down's syndrome. Prenat Diagn 16: 927-929

Watt HC, Wald NJ, Smith D, Kennard A, Densem J. (1996). Effect of allowing for ethnic group in prenatal screening for Down's syndrome. Prenat Diagn 16: 691-698

 

1995

Alberman E, Mutton D, Ide R, Nicholson A, Bobrow M. (1995). Down's syndrome births and pregnancy terminations in 1989 to 1993: preliminary findings. Br J Obstet Gynaecol 102: 445-447

Densem J, Wald NJ. (1995). Down's syndrome screening: value of using free b -hCG. Prenat Diagn 15: 94-95

Hackshaw AK, Densem J, Wald NJ. (1995). Repeat maternal serum testing for Down's syndrome screening using multiple markers with special reference to free a ; and free b . Prenat Diagn 15: 1125-1130

Hackshaw AK, Kennard A, Wald NJ. (1995). Detection of pregnancies with trisomy 18 in screening programmes for Down's syndrome. J Med Screen 2: 228-229

Hook EB, Mutton D, Ide R, Alberman E, Bobrow M. (1995). The natural history of Down syndrome conceptuses diagnosed prenatally that are not electively terminated. Am J Hum Genet 57: 875-881

Kennard A, Wald NJ. (1995). Antenatal screening for Down's syndrome. The Yearbook of the RCOG 1994. Studd J (Ed). London: RCOG Press; 229-243

Law MR. (1995). The health service and personal costs of screening. J Med Screen 2: 61

Macintosh MCM, Wald NJ, Chard T, Hansen J, Mikkelsen M, Therkelsen AJ, Petersen GB, Lundsteen C. (1995). The selective miscarriage of Down's syndrome from 10 weeks of pregnancy. Br J Obstet Gynaecol 102: 798-801. (Correction: Br J Obstet Gynaecol 103: 1172-1173)

Muttukrishna S, George L, Fowler PA, Groome NP, Knight PG. (1995). Measurement of serum concentrations of inhibin-A ( a ;- b A dimer) during human pregnancy. Clin Endocrinol 42: 391-397

Noble J, Wald NJ. (1995). Folic acid supplementation for prevention of neural tube defects. Genetics and Teratology 3(6)

Palomaki GE, Haddow JE, Knight GJ, Wald NJ, Kennard A, Canick JA, Saller DN, Blitzer MG, Dickerman LH, Fisher R, Hansmann D, Hansmann M, Luthy DA, Summers AM, Wyatt P. (1995). Risk-based prenatal screening for trisomy 18 using alpha-fetoprotein, unconjugated estriol and human chorionic gonadotropin. Prenat Diagn 15: 713-723

Wald NJ. (1995). Antenatal screening for Down's syndrome. In: Etiology and Pathogenesis of Down Syndrome. Epstein CJ, Hassold T, Lott IT, Nadel L, Patterson D (Eds). New York: Wiley; 27-41

Wald NJ. (1995). Biochemical detection of neural tube defects and Down's syndrome. Turnbull's Obstetrics (Second Edition). Chamberlain G (Ed). Edinburgh: Churchill Livingstone; 195-209

Wald NJ. (1995). Folic acid and the prevention of neural tube defects: the need for public health action. The scientific basis for vitamin intake in human nutrition. Bibl Nutr Dieta 52: 56-65

Wald N. (1995). Intervention studies on the role of folic acid in preventing neural tube defects. In: Folic Acid for the Prevention of Neural Tube Defects. Koren G (Ed). Toronto: The Motherisk Program; 57-63

Wald NJ, Bower C. (1995). Folic acid and the prevention of neural tube defects: a population strategy is needed. BMJ 310: 1019-1020

Wald NJ, Densem JW, Kennard A. (1995). Down's syndrome screening in twin pregnancies. Prenat Diagn 15: 387

Wald NJ, Gilbertson MP. (1995). Folic acid in prevention of neural tube defects. Lancet 345: 389

Wald NJ, Kennard A, Hackshaw AK. (1995). First trimester serum screening for Down's syndrome. Prenat Diagn (Review Issue) 15: 1227-1240

Wald NJ, Kennard A, Watt H, Haddow JE, Palomaki GE, Knight GJ, Canick JA. (1995). Costs were overestimated. BMJ 311: 1372

 

1994

Cuckle H, Densem J, Wald N. (1994). Repeat maternal serum testing in multiple marker Down's syndrome screening programmes. Prenat Diagn 14: 603-607

de Courcy-Wheeler RHB, Pomeranz MM, Wald NJ, Nicolaides KH. (1994). Small fetal transverse cerebellar diameter: a screening test for spina bifida. Br J Obstet Gynaecol 101: 904-905

Morris JK, Mutton DE, Ide R, Alberman E, Bobrow M. (1994). Monitoring trends in prenatal diagnosis of Down's syndrome in England and Wales 1989-92. J Med Screen 1: 233-237

Wald NJ. (1994). Folic acid and neural tube defects: the current evidence and implications for prevention. In: Neural Tube Defects (CIBA Foundation Symposium 181). Chichester: Wiley; 192-211

Wald NJ. (1994). The prevention of neural tube defects. Federation Focus 18: 8-9

Wald NJ, Bower C. (1994). Folic acid, pernicious anaemia, and prevention of neural tube defects. Lancet 343: 307

Wald NJ, Densem JW. (1994). Maternal serum free b -human chorionic gonadotrophin levels in twin pregnancies: Implications for screening for Down's syndrome. Prenat Diagn 14: 319-320

Wald NJ, Densem JW. (1994). Maternal serum free a ;-human chorionic gonadotrophin levels in twin pregnancies: Implications for screening for Down's syndrome. Prenat Diagn 14: 717-719

Wald NJ, Densem JW. (1994). Primary prevention, screening and diagnosis of neural tube defects. In: Obstetric Ultrasound 2. Neilson JP, Chambers SE (Eds). Oxford: Oxford University Press; 50-72

Wald NJ, Densem JW, Cheng R, Collishaw S. (1994). Maternal serum free a ;- and free b -human chorionic gonadotrophin in pregnancies with insulin-dependent diabetes mellitus: Implications for screening for Down's syndrome. Prenat Diagn 14: 835-837

Wald NJ, Densem JW, Smith D, Klee GG. (1994). Four marker serum screening for Down's syndrome. Prenat Diagn 14: 707-716

Wald NJ, Densem JW, Stone R, Cheng R. (1994). The use of free b -hCG in antenatal screening for Down's syndrome. Br J Obstet Gynaecol 101: 176-177

Wald NJ, Kennard A, Smith D. (1994). First trimester biochemical screening for Down's syndrome. Ann Med 26: 23-29

Wald NJ, Kennard A, Watt HC, Smith D. (1994). Value of maternal serum unconjugated oestriol measurement in prenatal screening for Down's syndrome. Prenat Diagn 14: 699-706.

Wald NJ, Watt HC. (1994). Choice of serum markers in antenatal screening for Down's syndrome. J Med Screen 1: 117-120